Aspirin not a cost effective substitute for colorectal cancer screening

November 05, 2001

Some animal studies have shown that aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) have an anti-tumor effect in the colon. Also, some studies in people suggest that these drugs may decrease the risk of colorectal cancer.

However, researchers at UCSF and the University of Michigan have determined in a recent study that aspirin is not a cost-effective addition to the national strategy for reducing death from colorectal cancer.

"While aspirin may be of some benefit in colorectal cancer prevention, it should not replace known screening methods," said Uri Ladabaum, MD, MS, UCSF assistant professor of gastroenterology and lead author of the study, which appears in the November 6 issue of the Annals of Internal Medicine.

"In addition, in terms of cost and benefits, it does not make sense for patients already getting regular screening to take aspirin to prevent colorectal cancer. Screening is highly cost-effective and remains so, even in patients already taking aspirin for other reasons like arthritis or prevention of heart disease."

Screening tests, including flexible sigmoidoscopy every five years and yearly fecal occult blood testing (FS/FOBT) or screening colonoscopy every ten years (COLO), remain the best strategies for preventing death from colorectal cancer in men and women, according to the researchers.

Though colorectal cancer screening is highly effective, less than half of the population seek it, said Mark Fendrick, MD, associate professor of medicine at the University of Michigan and a co-investigator on the study. He explained that increasing adherence to screening should be the primary goal on the national agenda for preventing death from colorectal cancer.

"Most colorectal cancers develop from benign growths in the colon called polyps. Screening can detect polyps, and removing polyps can prevent a large fraction of all colorectal cancers," said Ladabaum. "In addition, screening can detect cancers early, before any symptoms have developed. By the time symptoms develop, it is often too late to treat the cancer successfully."

Researchers constructed a computer simulation of the natural history of colorectal cancer in patients at average risk for the disease. In the model, investigators assumed aspirin could reduce colorectal cancer deaths by 30 percent.

Aspirin actually increased costs and resulted in loss of life-years when used as an adjunct to FS/BOBT. Under all circumstances, the complications associated with aspirin (bleeding, perforated ulcer, and death) were an important determinant of cost effectiveness, according to the researchers.

Aspirin cost $149, 161 per life-year gained as an adjunct to COLO. "This is the amount of money that needs to be spent by a third party payer to cover screening, aspirin, cancer care and the complications," said Ladabaum. "In general, interventions that society is willing to pay for are in the range of $50,000 or less per life year gained."

Screening fits within those parameters, he explained. It cost less than $25,000 per life-year gained and was more effective than aspirin alone. In patients already taking aspirin, screening with FS/BOBT or COLO cost less than $31,000 per life-year gained.

"This highlights the need to study safer chemo-prevention alternatives," said James Scheiman, MD, associate professor of medicine at the University of Michigan and a co-investigator on the study. He added that cyclooxygenase-2 (COX-2) inhibitors may prove to be safer, but more costly.

The computer model estimated clinical and economic consequences of six strategies:

1) no aspirin or screening
2) FS/FOBT
3) COLO
4) aspirin alone (ASA)
5) FS/FOBT and aspirin
6) COLO and aspirin.

Beginning at 50 years of age, patients progressed through the model for 30 one-year cycles. Principal disease states were defined as: normal, polyp, cancer (localized, regional or disseminated), and deceased. Researchers assumed that 90 percent of cancers develop from polyps and that cancer progresses from localized to regional to disseminated.

Procedure costs were derived from Medicare fee schedules and included professional fees and median procedure reimbursement. Researchers used the wholesale cost of aspirin at the University of Michigan pharmacy. Costs for cancer care of stage-specific colon cancer were taken from reports to the National Cancer Institute. All costs were in 1998 dollars.
-end-
This study was funded by grants from the National Institutes of Health to the University of Michigan and UC San Francisco.

NOTE TO THE MEDIA: For access to video news release (shot at UCSF with Dr. Ladabaum and a UCSF patient) feed times on November 5, 2001 are as follows:

9:00-9:30 a.m. (EST): Telestar 6, transponder 11, C-band. Downlink Freq: 3920 (V)

2:00-2:30 p.m. (EST): Same coordinates

For those who need a hard copy, contact Maya Burghardt at On the Scene Productions: 323-930-1030, mburghardt@onthescene.com

University of California - San Francisco

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.